JETREA Strength — DIN 02452154
Active ingredient(s) See footnote 8 : Strength OCRIPLASMIN : 1.25 MG / ML · THROMBOGENICS NV Gaston Geenslaan 1 Leuven Flemish Brabant Belgium 3001 · Solution · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is JETREA?
JETREA Strength contains Active ingredient(s) See footnote 8 : Strength OCRIPLASMIN : 1.25 MG / ML. It is listed in the Health Canada Drug Product Database under DIN 02452154, held by THROMBOGENICS NV Gaston Geenslaan 1 Leuven Flemish Brabant Belgium 3001, supplied as Solution for Intravitreal administration. Health Canada currently lists it as cancelled post market, status dated 20-Mar-2020. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is JETREA used for?
Treatment of symptomatic vitreomacular adhesion (VMA).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Ocriplasmin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Ocriplasmin — 2 DINs, of which 0 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| THROMBOGENICS NV Gaston Geenslaan 1 Leuven Flemish Brabant Belgium 3001 | 2 | 0 | JETREA | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | Strength |
|---|---|
| Dosage form | Solution |
| Route | Intravitreal |
| Pack configuration (monograph) | Single-use 2 mL glass vial containing 0.375 mg ocriplasmin in 0.3 mL solution. |
| Storage | Store in a freezer at -20°C ± 5°C. Protect from light. May be stored in refrigerator (2°C to 8°C) for up to 1 week after thawing. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Ocriplasmin |
|---|---|
| ATC code | S01XA22 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02452154 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2452154 |
| Brand name | JETREA |
| Generic / active ingredient | Active ingredient(s) See footnote 8 : Strength OCRIPLASMIN : 1.25 MG / ML |
| Market authorization holder | THROMBOGENICS NV Gaston Geenslaan 1 Leuven Flemish Brabant Belgium 3001 |
| Health Canada schedule | SCHEDULE D |
| ATC code | S01XA22 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01XA |
| Current status | CANCELLED POST MARKET |
| Status date | 20-Mar-2020 |
| Original market date | 2019-05-08 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
0.125 mg (0.1 mL) administered by intravitreal injection to the affected eye once as a single dose. Administered by a qualified health professional under aseptic conditions.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to ocriplasmin or excipients; active or suspected ocular or periocular infections.
Warnings and precautions
Risk of intraocular inflammation/infection, hemorrhage, increased IOP, retinal detachment, lens subluxation, and transient loss of visual acuity. Not recommended for concurrent bilateral use.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| JETREA | Strength | Solution | THROMBOGENICS NV Gaston Geenslaan 1 Leuven Flemish Brabant Belgium 3001 | CANCELLED POST MARKET | 02410818 |
2 · Same class — other molecules in ATC S01XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Artificial Tears And Other Indifferent Preparations. | ALCON TEARS 0.5% · ALCON TEARS 1% · AMO ENDOSOL EXTRA · AMO ENDOSOL SOLUTION · +84 more | 94 | 26 | Yes |
| Ciclosporin | CEQUA · RESTASIS · RESTASIS MULTIDOSE · TEVA-CYCLOSPORINE | 4 | 4 | Yes |
| Mercaptamine | CYSTADROPS | 1 | 1 | Yes |
| Voretigene Neparvovec | LUXTURNA | 1 | 1 | Yes |
| Ocriplasmin | JETREA | 2 | 0 | Not in Canada |
| Sodium Chloride, Hypertonic | EYESALINE EYEWASH · MURO 128 OPH SOLN 2% | 2 | 0 | Not in Canada |
| Cenegermin | OXERVATE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.